Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis

A. C. Kai; C. Flohr; C. E. Grattan

doi:10.1111/ced.12320

Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis

A. C. Kai
, C. Flohr
, C. E. Grattan

Women & Children's Health

St John's Institute of Dermatology
Cutaneous Allergy

Research output: Contribution to journal › Letter › peer-review

25 Citations (Scopus)

Original language	English
Pages (from-to)	651-652
Number of pages	2
Journal	Clinical and Experimental Dermatology
Volume	39
Issue number	5
DOIs	https://doi.org/10.1111/ced.12320
Publication status	Published - Jul 2014

Access to Document

10.1111/ced.12320

Cite this

@article{826ea0db076b4272b1507227e0a6fa66,

title = "Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis",

author = "Kai, \{A. C.\} and C. Flohr and Grattan, \{C. E.\}",

year = "2014",

month = jul,

doi = "10.1111/ced.12320",

language = "English",

volume = "39",

pages = "651--652",

journal = "Clinical and Experimental Dermatology",

issn = "0307-6938",

publisher = "Oxford University Press",

number = "5",

}

Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis. / Kai, A. C.; Flohr, C.; Grattan, C. E.
In: Clinical and Experimental Dermatology, Vol. 39, No. 5, 07.2014, p. 651-652.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis

AU - Kai, A. C.

AU - Flohr, C.

AU - Grattan, C. E.

PY - 2014/7

Y1 - 2014/7

UR - https://www.scopus.com/pages/publications/84902548320

U2 - 10.1111/ced.12320

DO - 10.1111/ced.12320

M3 - Letter

C2 - 24758481

AN - SCOPUS:84902548320

SN - 0307-6938

VL - 39

SP - 651

EP - 652

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

IS - 5

ER -

Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis

Access to Document

Other files and links

Cite this